Vanguard Group Inc Pharma Cyte Biotech, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 192,387 shares of PMCB stock, worth $309,743. This represents 0.0% of its overall portfolio holdings.
Number of Shares
192,387
Previous 192,387
-0.0%
Holding current value
$309,743
Previous $377,000
2.65%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding PMCB
# of Institutions
29Shares Held
931KCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6209KShares$336,9180.19% of portfolio
-
Geode Capital Management, LLC Boston, MA168KShares$270,8020.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$148,2607.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$133,1900.17% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.7KShares$80,0170.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $33.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...